CN106133519B - Gip上升抑制剂的评价或选择方法 - Google Patents
Gip上升抑制剂的评价或选择方法 Download PDFInfo
- Publication number
- CN106133519B CN106133519B CN201580015560.7A CN201580015560A CN106133519B CN 106133519 B CN106133519 B CN 106133519B CN 201580015560 A CN201580015560 A CN 201580015560A CN 106133519 B CN106133519 B CN 106133519B
- Authority
- CN
- China
- Prior art keywords
- fabp4
- protein
- fabp5
- genes
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-060341 | 2014-03-24 | ||
| JP2014060341 | 2014-03-24 | ||
| JP2015040187A JP6223376B2 (ja) | 2014-03-24 | 2015-03-02 | Gip上昇抑制剤の評価又は選択方法 |
| JP2015-040187 | 2015-03-02 | ||
| PCT/JP2015/056603 WO2015146537A1 (ja) | 2014-03-24 | 2015-03-06 | Gip上昇抑制剤の評価又は選択方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106133519A CN106133519A (zh) | 2016-11-16 |
| CN106133519B true CN106133519B (zh) | 2018-01-09 |
Family
ID=54195063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580015560.7A Expired - Fee Related CN106133519B (zh) | 2014-03-24 | 2015-03-06 | Gip上升抑制剂的评价或选择方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10132795B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3124966B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6223376B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106133519B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015146537A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6677455B2 (ja) * | 2015-05-14 | 2020-04-08 | 花王株式会社 | 毛成長抑制剤の評価又は選択方法 |
| CN114981446A (zh) * | 2020-01-17 | 2022-08-30 | 日本乐敦制药株式会社 | 组织形态、组织功能控制剂的评价/筛选方法 |
| CN116908157B (zh) * | 2023-07-14 | 2026-05-29 | 杭州环特生物科技股份有限公司 | 一种评价药物和保健食品调节食欲的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| EE200100155A (et) | 1998-09-17 | 2002-08-15 | Bristol-Myers Squibb Company | Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni |
| US7358254B2 (en) | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
| JP2004065194A (ja) * | 2002-08-09 | 2004-03-04 | Sumitomo Chem Co Ltd | 脂肪細胞関連因子の分析方法 |
| PT2403605E (pt) | 2009-03-05 | 2015-08-05 | Harvard College | Composições contendo um anticorpo específico de ap2 ou um seu fragmento, para serem utilizadas no tratamento de diabetes, intolerância à glicose ou resistência à insulina induzida por obesidade |
| JP5815928B2 (ja) | 2009-07-16 | 2015-11-17 | 花王株式会社 | 血中gip濃度上昇抑制剤 |
| JP5317919B2 (ja) | 2009-10-05 | 2013-10-16 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
| JP5328595B2 (ja) * | 2009-10-05 | 2013-10-30 | 花王株式会社 | Gip上昇抑制剤の評価又は選択方法 |
| US9056066B2 (en) | 2011-01-12 | 2015-06-16 | Kao Corporation | Agent for suppressing elevation of blood GIP level, agent for suppressing elevation of blood insulin level, agent for lowering blood triglyceride level after meal ingestion, and agent for suppressing elevation of blood glucose level |
| JP6026723B2 (ja) | 2011-02-22 | 2016-11-16 | 花王株式会社 | Gip上昇抑制剤 |
| JP2012171914A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Gip上昇抑制剤 |
| CN102961388A (zh) | 2011-08-30 | 2013-03-13 | 三和淀粉工业株式会社 | 促进glp-1的分泌并且抑制gip的分泌的药剂 |
-
2015
- 2015-03-02 JP JP2015040187A patent/JP6223376B2/ja not_active Expired - Fee Related
- 2015-03-06 EP EP15769760.8A patent/EP3124966B1/en not_active Not-in-force
- 2015-03-06 US US15/128,666 patent/US10132795B2/en active Active
- 2015-03-06 CN CN201580015560.7A patent/CN106133519B/zh not_active Expired - Fee Related
- 2015-03-06 WO PCT/JP2015/056603 patent/WO2015146537A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015146537A1 (ja) | 2015-10-01 |
| EP3124966A4 (en) | 2017-09-27 |
| EP3124966A1 (en) | 2017-02-01 |
| US20170227526A1 (en) | 2017-08-10 |
| JP2015194481A (ja) | 2015-11-05 |
| EP3124966B1 (en) | 2020-04-29 |
| JP6223376B2 (ja) | 2017-11-01 |
| US10132795B2 (en) | 2018-11-20 |
| CN106133519A (zh) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | Hypertrophic adipocyte–derived exosomal miR‐802‐5p contributes to insulin resistance in cardiac myocytes through targeting HSP60 | |
| Shimobayashi et al. | Insulin resistance causes inflammation in adipose tissue | |
| Brooks et al. | Fermentable carbohydrate stimulates FFAR2-dependent colonic PYY cell expansion to increase satiety | |
| Jeon et al. | SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice | |
| Zadjali et al. | SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high‐fat‐diet‐fed mice | |
| Vidal et al. | The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis | |
| Vecchi et al. | Gluconeogenic signals regulate iron homeostasis via hepcidin in mice | |
| Daly et al. | Sensing of amino acids by the gut-expressed taste receptor T1R1-T1R3 stimulates CCK secretion | |
| Yang et al. | GPR119: a promising target for nonalcoholic fatty liver disease | |
| Cao et al. | PKR protects colonic epithelium against colitis through the unfolded protein response and prosurvival signaling | |
| Kim et al. | α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition CC chemokine receptor 2 | |
| Arifin et al. | Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119 | |
| Hayashi et al. | Adipose-specific CC motif chemokine ligand (CCL) 19 overexpression drives the mice to both insulin resistance and weight gain | |
| Arivazhagan et al. | The RAGE/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease | |
| Gong et al. | F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish | |
| JP6223376B2 (ja) | Gip上昇抑制剤の評価又は選択方法 | |
| Kiefer et al. | Intestinal retinol saturase is implicated in the development of obesity and epithelial homeostasis upon injury | |
| Majchrzak et al. | Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for the treatment of Obesity-Associated cancers | |
| Mirzoyan et al. | A Drosophila model targets Eiger/TNFα to alleviate obesity-related insulin resistance and macrophage infiltration | |
| JP6442403B2 (ja) | 代謝調節のための方法および組成物 | |
| Zhang et al. | Uncoupling protein 2 negatively regulates glucose-induced glucagon-like peptide 1 secretion | |
| JP6514282B2 (ja) | Gip上昇抑制剤の評価又は選択方法 | |
| Li et al. | Myeloid PGC1β attenuates high-fat-diet induced inflammation via mitochondrial fission/mtDNA/Nlrp3 pathway | |
| Han et al. | Activation of SIK2 inhibits gluconeogenesis and alleviates lipogenesis‐induced inflammatory response by SIK2‐CRTC2‐ACC1 in hepatocytes of large yellow croaker (Larimichthys crocea) | |
| García-Martínez et al. | Insulin drives glucose-dependent insulinotropic peptide expression via glucose-dependent regulation of FoxO1 and LEF1/β-catenin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180109 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |